K Number
K112478
Device Name
VISI MOBILE MONITORING SYSTEM
Date Cleared
2012-03-22

(206 days)

Product Code
Regulation Number
870.2300
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The ViSi Mobile Monitoring System is intended for use by clinicians and medically qualified personnel for single or multi-parameter vital signs monitoring of adult patients. It is indicated for ECG (3 or 5 leadwire), respiration rate (RESP), heart rate (HR), non-invasive blood pressure (NIBP), non-invasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2), pulse rate (PR), and skin temperature (TEMP) in hospital-based facilities; including general medical-surgical floors, intermediate care floors, and emergency departments.
Device Description
The ViSi Mobile Monitoring System is a lightweight, portable patient vital signs monitor featuring a high resolution, full color touch screen display, with visual and audible alarms and alerts. The ViSi Mobile Monitor is body-worn and designed to continuously measure ECG, heart rate, SpO2, pulse rate, respiration rate, and temperature. The ECG, SpO2, and Respiration waveforms are viewable on demand. NIBP can be measured as a onetime measurement, or it can be measured automatically at predefined intervals
More Information

Not Found

No
The document does not mention AI, ML, or any related terms, and the description focuses on standard vital sign monitoring technologies.

No

The device is described as a monitoring system that measures vital signs and provides alerts, but it does not perform any therapeutic or treatment functions.

No

The device is a vital signs monitor that measures and displays physiological parameters. It does not perform a diagnostic function by identifying or confirming the presence of a disease or condition.

No

The device description explicitly states it is a "lightweight, portable patient vital signs monitor featuring a high resolution, full color touch screen display" and is "body-worn," indicating it includes hardware components beyond just software.

Based on the provided information, the ViSi Mobile Monitoring System is not an In Vitro Diagnostic (IVD) device.

Here's why:

  • IVD devices are used to examine specimens derived from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
  • The ViSi Mobile Monitoring System directly monitors physiological vital signs from the patient's body (ECG, respiration rate, heart rate, NIBP, SpO2, pulse rate, temperature). It does not analyze samples taken from the body.

The device description and intended use clearly indicate that it is a patient monitoring system that measures vital signs in vivo (within the living body).

N/A

Intended Use / Indications for Use

The ViSi Mobile Monitoring System is intended for use by clinicians and medically qualified personnel for single or multi-parameter vital signs monitoring of adult patients. It is indicated for ECG (3 or 5 leadwire), respiration rate (RESP), heart rate (HR), non-invasive blood pressure (NIBP), non-invasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2), pulse rate (PR), and skin temperature (TEMP) in hospital-based facilities; including general medical-surgical floors, intermediate care floors, and emergency departments.

Product codes

MWI, DRT, DXN, DQA, FLL

Device Description

The ViSi Mobile Monitoring System is a lightweight, portable patient vital signs monitor featuring a high resolution, full color touch screen display, with visual and audible alarms and alerts. The ViSi Mobile Monitor is body-worn and designed to continuously measure ECG, heart rate, SpO2, pulse rate, respiration rate, and temperature. The ECG, SpO2, and Respiration waveforms are viewable on demand. NIBP can be measured as a onetime measurement, or it can be measured automatically at predefined intervals

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

adult patients

Intended User / Care Setting

clinicians and medically qualified personnel; hospital-based facilities; including general medical-surgical floors, intermediate care floors, and emergency departments.

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

The validity of this method was confirmed in an ISO 81060-2 compliant clinical study demonstrating that this method of blood pressure meets the requirements of the standard in terms of accuracy and variability.

The safety and effectiveness of the design elements implemented into the ViSi System have been confirmed by their compliance to the prevailing vital signs monitoring standards. The ViSi System has demonstrated compliance with the applicable sections of the following consensus standards: IEC 60601-1, IEC 60601-1-2, IEC 60601-1-4, IEC 60601-1-8, IEC 60601-2-27, IEC 60601-2-49, IEC 80601-2-30, ISO 9919, ASTM E1112, EC13, and EC53.

The ViSi System has successfully undergone safety testing as well as functional testing to demonstrate equivalence to the predicate devices. The following quality assurance measures were applied to the device: Risk analysis, Requirements review, Code inspections, Verification and validation, Bench testing, Clinical performance testing, Biocompatibility testing, and Safety testing

The ViSi System have been tested and found to comply with recognized national and international performance, safety, and electromagnetic compatibility standards for medical devices. The results of all the testing demonstrate that the ViSi System is safe, effective, complies with the appropriate medical device standards, and is substantially equivalent to the predicate devices.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K043517, K082812

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).

(a)
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.(b)
Classification. Class II (performance standards).

0

Image /page/0/Picture/0 description: The image shows a sequence of handwritten characters and numbers. The sequence starts with the letter 'K', followed by the number '1' twice, then the numbers '2', '4', '7', and '8'. The characters are written in a simple, slightly irregular style, typical of handwriting.

MAR 2 2 2012

Image /page/0/Picture/2 description: The image shows the logo for Sotera Wireless. The logo consists of the word "Sotera" in a bold, sans-serif font, with a small graphic above the word. The graphic appears to be a stylized representation of radio waves. Below the word "Sotera" is the word "WIRELESS" in a smaller, sans-serif font.

www.soterawireless.com

510(k) Summary

Date preparedNovember 20, 2011
NameSotera Wireless. Inc.
9444 Waples Street, Suite 280
San Diego, CA 92121
T. 858.427.4620; F. 858.427.4639
Contact personEben Gordon
Senior Director, Regulatory
Trade nameViSi Mobile Monitoring System
Common nameVital signs monitor
Classification nameCardiac monitor (including cardiotachometer and rate alarm)
Classification regulationMonitor, physiological, patient(without arrhythmia detection or alarms; 21
CFR 870.2300 (MWI)
Predicate deviceNihon Kohden ZS-940PA
K043517, Clearance date: February 3, 2005
Omron Healthcare, Inc., HBP-2070
K082812, Clearance date: October 22, 2008
DescriptionThe ViSi Mobile Monitoring System is a lightweight, portable patient vital
signs monitor featuring a high resolution, full color touch screen display,
with visual and audible alarms and alerts. The ViSi Mobile Monitor is
body-worn and designed to continuously measure ECG, heart rate, SpO2,
pulse rate, respiration rate, and temperature. The ECG, SpO2, and
Respiration waveforms are viewable on demand. NIBP can be measured as
a onetime measurement, or it can be measured automatically at predefined
intervals
Indications for useThe ViSi Mobile Monitoring System is intended for use by clinicians and
medically qualified personnel for single or multi-parameter vital signs
monitoring of adult patients. It is indicated for ECG (3 or 5 leadwire),
respiration rate (RESP), heart rate (HR), non-invasive blood pressure
(NIBP), non-invasive monitoring of functional oxygen saturation of arterial
hemoglobin (SpO2), pulse rate (PR), and skin temperature (TEMP) in
hospital-based facilities; including general medical-surgical floors,
intermediate care floors, and emergency departments.
Summary of substantial
equivalenceThe ViSi System has the following similarities and differences with the
indicated predicate devices:
Intended use - The ViSi System and the predicate devices have the
same intended uses as the predicate devices: vital signs monitoring.

1

While NIBP is measured using oscillation for all three devices, the ViSi System determines blood pressure on inflation rather than deflation. The validity of this method was confirmed in an ISO 81060-2 compliant clinical study demonstrating that this method of blood pressure meets the requirements of the standard in terms of accuracy and variability.

The Nihon Kohden device has the capability to transmit data wirelessly in addition to local display and alarming while the ViSi System differs in that it only has the capability to display and alarm locally (i.e. does not transmit data wirelessly). Similar to the Omron HBP-2070, the ViSi does not transmit data for remote viewing.

  • Design ViSi System and the Nihon Kohden ZS-940PA have . similar form factors in that they both are patient worn. The Omron HBP-2070 is not attached to the patient.
    The safety and effectiveness of the design elements implemented into the ViSi System have been confirmed by their compliance to the prevailing vital signs monitoring standards. The ViSi System has demonstrated compliance with the applicable sections of the following consensus standards: IEC 60601-1, IEC 60601-1-2, IEC 60601-1-4, IEC 60601-1-8, IEC 60601-2-27, IEC 60601-2-49, IEC 80601-2-30, ISO 9919, ASTM E1112, EC13, and EC53.

  • General Safety and Effectiveness Concerns The instructions for . use for the ViSi System contains the necessary cautions and warnings to provide for safe and effective use of the device.
    The ViSi System has successfully undergone safety testing as well as functional testing to demonstrate equivalence to the predicate devices. The following quality assurance measures were applied to the device: Risk analysis, Requirements review, Code inspections, Verification and validation, Bench testing, Clinical performance testing, Biocompatibility testing, and Safety testing

The ViSi System have been tested and found to comply with recognized national and international performance, safety, and electromagnetic compatibility standards for medical devices. The results of all the testing demonstrate that the ViSi System is safe, effective, complies with the appropriate medical device standards, and is substantially equivalent to the predicate devices.

2

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three stylized, curved lines.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

MAR 2 2 2012

Sotera Wireless, Inc. c/o Mr. Eben Gordon Sr. Director, Regulatory Affairs 9444 Waples St., Suite 280 San Diego, CA 92121

Re: K112478

Trade/Device Names: Visi Mobile Monitoring System, Model (H1,1a) Regulatory Number: 21 CFR 870.2300 Regulation Name: Cardiac Monitor (including Cardiotachometer and Rate Alarm) Regulatory Class: Class II (Two) Product Code: MWI, DRT, DXN, DQA and FLL Dated: March 2, 2012 Received: March 5, 2012

Dear Mr. Gordon:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

3

Page 2 - Mr. Eben Gordon

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

4

4 INDICATIONS FOR USE

510(k) Number (if known):

Device Name: ______________________________________________________________________________________

K112478

Indications for Use:

The ViSi Mobile Monitoring System is intended for use by clinicians and medically qualified personnel for single or multi-parameter vital signs monitoring of adult patients. It is indicated for ECG (3 or 5 leadwire), respiration rate (RESP), heart rate (HR), non-invasive blood pressure (NIBP), non-invasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2), pulse rate (PR), and skin temperature (TEMP) in hospital-based facilities; including general medical-surgical floors, intermediate care floors, and emergency departments.

Prescription Use __

AND/OR

Over the Counter Use _________________________________________________________________________________________________________________________________________________________

(Part 21 CFR 801 Subpart D)

(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of Cardiovascular Devices
Page 1 of 1
---------------
8/25/2011510(k) Number K112478Page 12
-------------------------------------------